Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner
Dimitri Lodygin, … , Antje Menssen, Heiko Hermeking
Dimitri Lodygin, … , Antje Menssen, Heiko Hermeking
Published December 1, 2002
Citation Information: J Clin Invest. 2002;110(11):1717-1727. https://doi.org/10.1172/JCI16588.
View: Text | PDF
Article Aging

Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner

  • Text
  • PDF
Abstract

Research Article

Authors

Dimitri Lodygin, Antje Menssen, Heiko Hermeking

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Requirement of p21, but not p53, for inhibition of proliferation by LY. ...
Requirement of p21, but not p53, for inhibition of proliferation by LY. (a) Response of HCT116 colorectal cancer cells deficient for p21 to LY. Cells were treated with LY or, as a control, with vehicle (DMSO), and cell numbers were assessed. Measurements were performed in triplicates. (b) Response of p53+/+ and p53–/– HCT116 cells to LY. Cells were treated with LY or, as a control, with vehicle (DMSO), and cell numbers were assessed. Measurements were performed in triplicates. (c) Analysis of HCT116-derived knockout cell lines. Shown are the results of Western blot analysis of p53 and p21 protein levels after addition of adriamycin at 0.2 μg/ml for 8 hours. (d) p21 promoter reporter activity in p53-deficient HCT116 cells after treatment with 1.5 μM LY for 12 hours. The experiment was performed in triplicates. For details, see the Methods. (e) p53-independent induction of p21 mRNA by LY. Shown are the results of Northern blot analysis with RNA isolated at the indicated time points after addition of 1.5 μM LY to p53-deficient HCT116 cells. (f) p53-independent induction of p21 protein levels by LY. Shown are the results of Western blot analysis with lysates from p53–/– HCT116 cells treated with 1.5 μM LY. Membranes were probed with antibodies specific for p21 and, as a loading control, α-tubulin. For details, see the Methods.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts